Download the Protocol

Mazdutide

Mazdutide is a next-generation compound that helps the body manage weight and blood sugar by influencing appetite and fat burning. It works on two key hormone systems that regulate energy balance, helping people feel full while improving how the body uses fat for energy. It’s being studied for long-term use in obesity and diabetes research.

Description

• Mazdutide (LY3305677) is a dual GLP-1 and glucagon receptor agonist developed by Eli Lilly.
• Studied for the treatment of obesity and type 2 diabetes by enhancing fat oxidation and reducing appetite.
• Currently in late-stage clinical trials for long-term metabolic management.

How It Works

• Activates GLP-1 receptors to increase insulin secretion and satiety.
• Stimulates glucagon receptors to boost thermogenesis and fat utilization.
• Leads to reduced food intake and improved energy expenditure.

Documented Effects

• Produces sustained weight loss of 15–20% in clinical research at higher doses.
• Improves glucose tolerance, lipid metabolism, and hepatic fat reduction.
• Most common effects are mild nausea, fullness, and gastrointestinal discomfort.

Theoretical Effects

• May outperform single-agonist GLP-1 drugs (e.g., semaglutide) for metabolic improvement.
• Potential synergy with other incretin-based agents such as GIP or amylin analogues.
• Long-term benefits on cardiometabolic and liver health remain under study.

Pharmacokinetics

• Half-life: Approximately 6–8 days after subcutaneous injection.
• Time to peak concentration: 24–72 hours post-dose.
• Steady-state: Reached within 4–6 weeks of consistent weekly dosing.

Duration of Effects

• Provides stable metabolic and appetite effects for 7–10 days per injection.
• Improved glucose and fat metabolism persists with continued weekly administration.
• Benefits gradually fade over 2–3 weeks after discontinuation.

Reconstitution

• Use only bacteriostatic water to mix the lyophilized powder.
• Example vial: 10 mg of Mazdutide
• Choose reconstitution volume based on dosing convenience:
  • 1 mL water → 10 mg/mL → 1 mg per 10 units
  • 2 mL water → 5 mg/mL → 500 mcg per 10 units
• Swirl gently to dissolve; avoid shaking.
• Refrigerate reconstituted solution (2–8 °C). Use within ~30 days for best stability.

Injectable Dosage Overview (First-Time Use)

Typical Starting Dose

• Injectable (clinical research): ~3 mg subcutaneous (SC) once weekly.
• Conservative entry point: start at 3 mg and increase gradually to minimize nausea.

Common Therapeutic Range

• Typical clinical range: 6–12 mg SC once weekly depending on response and tolerance.
• Used primarily for obesity and metabolic regulation in research settings.

Maximum Weekly Dose

• Studies have tested up to ~12 mg weekly.
• Higher doses show diminishing returns and increased gastrointestinal effects.

Standard Cycle Length

• Long-term therapy: 24–64 weeks continuous administration in research trials.
• Intended for sustained metabolic benefit, not short-term cycles.

Clinical Notes

• Inject subcutaneously in the abdomen, thigh, or upper arm once weekly.
• Rotate injection sites to minimize irritation.
• Titrate gradually every 4–6 weeks to improve tolerability.
• Stable for about 30 days when refrigerated (2–8°C). Protect from light and heat. Avoid freezing.

Safety Notes (First-Time Use)

• Begin with low dose (3 mg) to minimize nausea and digestive discomfort.
• Possible effects: transient nausea, fullness, mild fatigue.
• Do not combine with other GLP-1 or incretin-based agents unless supervised in a research context.
• Contraindicated in subjects with medullary thyroid carcinoma or MEN2.
• Long-term human safety data remain under evaluation.